Literature DB >> 7952386

The impact of stressors on immune and central neurotransmitter activity: bidirectional communication.

H Anisman1, S Zalcman, R M Zacharko.   

Abstract

Antigenic challenge may have broad ranging effects which include not only immunological changes, but also endocrine and central neurotransmitter repercussions, and may thus elicit profound behavioral sequelae. Commensurate with the notion that bidirectional communication exists between the immune and central nervous systems it has been demonstrated that manipulations which influence central neurotransmitter or endocrine activity provoke alterations of immune functioning, and conversely immunological alterations will affect central neurotransmitter and endocrine activity. It seems, as well, that environmental stressors may provoke marked alterations of the activity of each of these systems. Indeed, in several respects the variables that influence vulnerability to stressor-provoked neurotransmitter changes, likewise affect the immunological alterations engendered by stressors. Moreover, immunological challenges will affect central neurotransmitter functioning in much the same way as stressors provoke such effects. It is thought that immune derived products (including cytokines as well as peptide hormones) may act directly or indirectly to moderate neurotransmitter functioning, and centrally derived neurotransmitters and hormones may affect receptors present on lymphocytes. In accordance with earlier suggestions, it is maintained that the immune system may be acting as a sensory organ informing the brain of the presence of antigenic challenges, and the brain may interpret such challenge as a stressor, hence leading to behavioral alterations.

Mesh:

Substances:

Year:  1993        PMID: 7952386     DOI: 10.1515/revneuro.1993.4.2.147

Source DB:  PubMed          Journal:  Rev Neurosci        ISSN: 0334-1763            Impact factor:   4.353


  7 in total

Review 1.  Neuroimmune mechanisms in health and disease: 1. Health.

Authors:  H Anisman; M G Baines; I Berczi; C N Bernstein; M G Blennerhassett; R M Gorczynski; A H Greenberg; F T Kisil; R D Mathison; E Nagy; D M Nance; M H Perdue; D K Pomerantz; E R Sabbadini; A Stanisz; R J Warrington
Journal:  CMAJ       Date:  1996-10-01       Impact factor: 8.262

Review 2.  Neuroimmune mechanisms in health and disease: 2. Disease.

Authors:  H Anisman; M G Baines; I Berczi; C N Bernstein; M G Blennerhassett; R M Gorczynski; A H Greenberg; F T Kisil; R D Mathison; E Nagy; D M Nance; M H Perdue; D K Pomerantz; E R Sabbadini; A Stanisz; R J Warrington
Journal:  CMAJ       Date:  1996-10-15       Impact factor: 8.262

3.  Dynamic interactions between plasma IL-1 family cytokines and central endogenous opioid neurotransmitter function in humans.

Authors:  Alan R Prossin; Steven S Zalcman; Mary M Heitzeg; Alisa E Koch; Phillip L Campbell; K Luan Phan; Christian S Stohler; Jon-Kar Zubieta
Journal:  Neuropsychopharmacology       Date:  2014-08-20       Impact factor: 7.853

4.  T-lymphocyte activation increases hypothalamic and amygdaloid expression of CRH mRNA and emotional reactivity to novelty.

Authors:  A W Kusnecov; R Liang; G Shurin
Journal:  J Neurosci       Date:  1999-06-01       Impact factor: 6.167

5.  Facilitated acquisition of the classically conditioned eyeblink response in male rats after systemic IL-1beta.

Authors:  Richard J Servatius; Kevin D Beck
Journal:  Integr Physiol Behav Sci       Date:  2003 Jul-Sep

6.  The Cox-2 Inhibitor Meloxicam Ameliorates Neuroinflammation and Depressive Behavior in Adult Mice after Splenectomy.

Authors:  Michael Haile; Allal Boutajangout; Kevin Chung; Jeffrey Chan; Tanya Stolper; Nemahun Vincent; Marc Batchan; John D'Urso; Yan Lin; Richard Kline; Faris Yaghmoor; Saad Jahfal; Robel Kamal; Waleed Aljohani; Thomas Blanck; Alex Bekker; Thomas Wisniewski
Journal:  J Neurophysiol Neurol Disord       Date:  2016-08-05

Review 7.  Positron emission tomography imaging of endogenous mu-opioid mechanisms during pain and migraine.

Authors:  Alexandre F DaSilva; Jon-Kar Zubieta; Marcos F DosSantos
Journal:  Pain Rep       Date:  2019-08-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.